Skip to main content
AstraZeneca Canada on Muck Rack

AstraZeneca Canada

As seen in: Lung Cancer
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with AstraZeneca

Contact AstraZeneca, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Development, Validation and Results from the Impact of Treatment Evolution in Non-Small Cell Lung Cancer (iTEN) Model

|
By Daniel M. Moldaver, William Evans, Manjusha Hurry, AstraZeneca Canada
| Lung Cancer Verified
To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect. Fig. 1 Model Structure Diagram. The model compares current Canadian aNSCLC practice patterns against the estimated future cost of care. Notes: *, Costs included are: drug acquisition and administration, recommended imaging and monitoring, physician visits, best supportive care and end of life care. Fig. 2 iTEN Model Validation.
Open in Who Shared Issue with article?
See all 1 articles